Recurrent Classical Hodgkin Lymphoma Recruiting Phase 1 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0070972 (Recurrent Classical Hodgkin Lymphoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03150329Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin LymphomaTreatment